Healthcare · Biotechnology · NASDAQ
| Market cap | $1.03B |
|---|---|
| Trailing P/E | — |
| Price / book | — |
| Price / sales | 69.0 |
| FCF yield | -6.9% |
| Dividend yield | — |
| Gross margin | 0.0% |
| Operating margin | -588.9% |
| Net margin | 0.0% |
| Revenue growth (YoY) | +388.2% |
| Revenue growth (3-yr annual) | — |
| EPS growth (YoY) | — |
| FCF/share growth (YoY) | — |
| Beta | — |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
Median target $34.00 from 3 analysts, ranging $32.00 – $46.00.
| Ticker | Company | Market cap | P/E |
|---|---|---|---|
| VRTX | Vertex Pharmaceuticals | $130.58B | 27.1 |
| REGN | Regeneron Pharmaceuticals | $95.24B | 16.7 |
| MRNA | Moderna | $78.90B | — |
| ARGX | argenx | $58.21B | 32.3 |
| ONC | BeOne Medicines | $44.66B | 49.7 |
| RPRX | Royalty Pharma | $39.36B | 12.9 |
| RVMD | Revolution Medicines | $34.87B | — |
| GMAB | Genmab A/S | $31.20B | 36.7 |